Pyroptosis-mediator GSDMD promotes parkinson's disease pathology via microglial activation and dopaminergic neuronal death

Brain Behav Immun. 2024 Mar 27:S0889-1591(24)00319-2. doi: 10.1016/j.bbi.2024.03.038. Online ahead of print.ABSTRACTGSDMD-mediated pyroptosis occurs in the nigrostriatal pathway in Parkinson's disease animals, yet the role of GSDMD in neuroinflammation and death of dopaminergic neurons in Parkinson's disease remains elusive. Here, our in vivo and in vitro studies demonstrated that GSDMD, as a pyroptosis executor, contributed to glial reaction and death of dopaminergic neurons across different Parkinson's disease models. The ablation of the Gsdmd attenuated Parkinson's disease damage by reducing dopaminergic neuronal death, microglial activation, and detrimental transformation. Disulfiram, an inhibitor blocking GSDMD pore formation, efficiently curtailed pyroptosis, thereby lessening the pathology of Parkinson's disease. Additionally, a modification in GSDMD was identified in the blood of Parkinson's disease patients in contrast to healthy subjects. Therefore, the detected alteration in GSDMD within the blood of Parkinson's disease patients and the protective impact of disulfiram could be promising for the diagnostic and therapeutic approaches against Parkinson's disease.PMID:38552923 | DOI:10.1016/j.bbi.2024.03.038
Source: Brain, Behavior, and Immunity - Category: Neurology Authors: Source Type: research